Autoimmune and neoplastic thyroid diseases associated with hepatitis c chronic infection

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Fallahi, Poupak ^a   Ferrari, Silvia Martina ^a   Politti, Ugo ^a   Giuggioli, Dilia ^b   Ferri, Clodoveo ^b   Antonelli, Alessandro ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE THYROIDITIS; CRYOGLOBULINEMIA; CXCL10 GENE; CYTOKINE RELEASE; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS C; HUMAN; IMMUNOPATHOGENESIS; MYXEDEMA; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; SUBCLINICAL HYPOTHYROIDISM; TH1 CELL; TH2 CELL; THYROID PAPILLARY CARCINOMA; THYROTOXICOSIS; UPREGULATION;

EID: 84908336123     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/935131     Document Type: Review

References (129)

1. Alter M. J., Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 2007 13 17 2436 2441 10.3748/wjg.v13.i17.2436 2-s2.0-34250679750
2. Blackard J. T., Kemmer N., Sherman K. E., Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006 44 1 15 22 10.1002/hep.21283 2-s2.0-33745880701
3. Stefanova-Petrova D. V., Tzvetanska A. H., Naumova E. J., Mihailova A. P., Hadjiev E. A., Dikova R. P., Vukov M. I., Tchernev K. G., Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World Journal of Gastroenterology 2007 13 48 6518 6528 10.3748/wjg.13.6518 2-s2.0-38349014400
4. Galossi A., Guarisco R., Bellis L., Puoti C., Extrahepatic manifestations of chronic HCV infection. Journal of Gastrointestinal and Liver Diseases 2007 16 1 65 73 2-s2.0-34047275552
5. Ferri C., Antonelli A., Mascia M. T., Sebastiani M., Fallahi P., Ferrari D., Giunti M., Pileri S. A., Zignego A. L., B-cells and mixed cryoglobulinemia. Autoimmunity Reviews 2007 7 2 114 120 10.1016/j.autrev.2007.02.019 2-s2.0-36148982259
6. Ferri C., Antonelli A., Mascia M. T., Sebastiani M., Fallahi P., Ferrari D., Pileri S. A., Zignego A. L., HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Digestive and Liver Disease 2007 39 1 S13 S21 10.1016/S1590-8658(07)80005-3 2-s2.0-35148896751
7. Ferrari S. M., Fallahi P., Mancusi C., Colaci M., Manfredi A., Ferri C., Antonelli A., HCV-related autoimmune disorders in HCV chronic infection. La Clinica Terapeutica 2013 164 4 e305 e312 10.7417/CT.2013.1594 2-s2.0-84885799512
8. Fallahi P., Ferrari S. M., Giuggioli D., Corrado A., Fabiani S., Marchi S., Ferri C., Antonelli A., Mixed cryoglobulinemia and thyroid autoimmune disorders. Clinica Terapeutica 2013 164 4 e337 e341 10.7417/CT.2013.1598 2-s2.0-84885716694
9. Cheng Z. J., Zhou B. T., Shi X. C., Zhang Y., Zhang L. F., Chen L. M., Liu X. Q., Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chinese Medical Journal 2014 127 7 1206 1210 10.3760/cma.j.issn.0366-6999.20132988 2-s2.0-84897948061
10. Blackard J. T., Kong L., Huber A. K., Tomer Y., Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid 2013 23 7 863 870 10.1089/thy.2012.0507 2-s2.0-84881434907
11. Palazzi C., Buskila D., D'Angelo S., D'Amico E., Olivieri I., Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmunity Reviews 2012 11 9 659 663 10.1016/j.autrev.2011.11.011 2-s2.0-84861751183
12. Saadoun D., Landau D. A., Calabrese L. H., Cacoub P. P., Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology 2007 46 8 1234 1242 10.1093/rheumatology/kem132 2-s2.0-34547852182
13. Cicardi M., Cesana B., Del Ninno E., Pappalardo E., Silini E., Agostoni A., Colombo M., Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. Journal of Viral Hepatitis 2000 7 2 138 143 10.1046/j.1365-2893.2000.00204.x 2-s2.0-0034108710
14. Lunel F., Musset L., Cacoub P., Frangeul L., Cresta P., Perrin M., Grippon P., Hoang C., Piette J. C., Huraux J.-M., Opolon P., Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 1994 106 5 1291 1300 2-s2.0-0028274816
15. Fallahi P., di Domenicantonio A., Mazzi V., Santini F., Fabiani S., Sebastiani M., Zignego A. L., Ferri C., Antonelli A., Hepatitis c virus and type 1 diabetes. Clinica Terapeutica 2013 164 5 e437 e444 10.7417/CT.2013.1624 2-s2.0-84888105681
16. Fallahi P., Ferrari S. M., Colaci M., Ruffilli I., Vita R., Azzi A., Ferri C., Antonelli A., Ferrannini E., Hepatitis C virus infection and type 2 diabetes. La Clinica Terapeutica 2013 164 5 e393 e404 10.7417/CT.2013.1620 2-s2.0-84888121240
17. Obermayer-Straub P., Manns M. P., Hepatitis C and D, retroviruses and autoimmune manifestations. Journal of Autoimmunity 2001 16 3 275 285 10.1006/jaut.2000.0488 2-s2.0-0034979277
18. McLeod D. S. A., Cooper D. S., The incidence and prevalence of thyroid autoimmunity. Endocrine 2012 42 2 252 265 10.1007/s12020-012-9703-2 2-s2.0-84867403047
19. Orgiazzi J., Thyroid autoimmunity. La Presse Médicale 2012 41 12 part 2 e611 e625 10.1016/j.lpm.2012.10.002 2-s2.0-84870677982
20. Caturegli P., de Remigis A., Rose N. R., Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmunity Reviews 2014 13 4-5 391 397 10.1016/j.autrev.2014.01.007 2-s2.0-84896319312
21. Corrado A., Ferrari S. M., Ferri C., Ferrannini E., Antonelli A., Fallahi P., Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine. Clinica Terapeutica 2014 165 2 e181 e185 10.7471/CT.2014.1706 2-s2.0-84899763519
22. Mancusi C., di Domenicantonio A., Politti U., Giuggioli D., Antonelli A., Ferri C., Fallahi P., The alpha chemokine "Interferon gamma-induced protein 10" (IP-10) in Graves' disease. Clinica Terapeutica 2014 165 2 e174 e180 10.7471/CT.2014.1705 2-s2.0-84899721348
23. Saranac L., Zivanovic S., Bjelakovic B., Stamenkovic H., Novak M., Kamenov B., Why is the thyroid so prone to autoimmune disease? Hormone Research in Paediatrics 2011 75 3 157 165 10.1159/000324442 2-s2.0-79951849864
24. Brent G. A., Environmental exposures and autoimmune thyroid disease. Thyroid 2010 20 7 755 761 10.1089/thy.2010.1636 2-s2.0-78349278501
25. Tomer Y., Genetic susceptibility to autoimmune thyroid disease: past, present, and future. Thyroid 2010 20 7 715 725 10.1089/thy.2010.1644 2-s2.0-78349272440
26. Duntas L. H., Environmental factors and thyroid autoimmunity. Annales d'Endocrinologie 2011 72 2 108 113 10.1016/j.ando.2011.03.019 2-s2.0-79955725584
27. Martino E., Macchia E., Aghini-Lombardi F., Antonelli A., Lenziardi M., Concetti R., Fenzi G. F., Baschieri L., Pinchera A., Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis (AIIT)? Clinical Endocrinology 1986 24 6 627 633 10.1111/j.1365-2265.1986.tb01658.x 2-s2.0-0022624523
28. Köhrle J., Selenium and the thyroid. Current Opinion in Endocrinology, Diabetes and Obesity 2013 20 5 441 448 10.1097/01.med.0000433066.24541.88 2-s2.0-84883656109
29. Antonelli A., Ferri C., Fallahi P., Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN- α therapy. Nature Reviews Gastroenterology and Hepatology 2009 6 11 633 635 10.1038/nrgastro.2009.168 2-s2.0-71049138502
30. Desailloud R., Hober D., Viruses and thyroiditis: an update. Virology Journal 2009 6, article 5 10.1186/1743-422X-6-5 2-s2.0-62249221293
31. Akeno N., Blackard J. T., Tomer Y., HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. Journal of Autoimmunity 2008 31 4 339 344 10.1016/j.jaut.2008.08.001 2-s2.0-56549131461
32. Minelli R., Braverman L. E., Giuberti T., Schianchi C., Gardini E., Salvi M., Fiaccadori F., Ugolotti G., Roti E., Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment. Clinical Endocrinology 1997 47 3 357 361 10.1046/j.1365-2265.1997.2721081.x 2-s2.0-0030827008
33. Tomer Y., Davies T. F., Infection, thyroid disease, and autoimmunity. Endocrine Reviews 1993 14 1 107 120 10.1210/er.14.1.107 2-s2.0-0027510452
34. Bartolomé J., Rodríguez-Iñigo E., Quadros P., Vidal S., Pascual-Miguelañez I., Rodríguez-Montes J. A., García-Sancho L., Carreño V., Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. Journal of Medical Virology 2008 80 9 1588 1594 10.1002/jmv.21269 2-s2.0-48249144341
35. Agnello V., De Rosa F. G., Extrahepatic disease manifestations of HCV infection: some current issues. Journal of Hepatology 2004 40 2 341 352 10.1016/j.jhep.2003.10.009 2-s2.0-1642491767
36. Duclos-Vallée J. C., Johanet C., Trinchet J. C., Deny P., Laurent M. F., Duron F., Valensi P., Weil B., Homberg J. C., Pateron D., Beaugrand M., High prevalence of serum antibodies to hepatitis C virus in patients with Hashimoto's thyroiditis. British Medical Journal 1994 309 6958 846 847 10.1136/bmj.309.6958.846 2-s2.0-0028168883
37. Yang R., Shan Z., Li Y., Fan C., Li C., Teng W., Prevalence of thyroid autoantibodies in hepatitis C and hepatits B infection in China. Internal Medicine 2011 50 8 811 815 10.2169/internalmedicine.50.4870 2-s2.0-79955555252
38. Marconcini M. L., Fayad L., Shiozawa M. B. C., Dantas-Correa E. B., de Lucca Schiavon L., Narciso-Schiavon J. L., Autoantibody profile in individuals with chronic hepatitis C. Revista da Sociedade Brasileira de Medicina Tropical 2013 46 2 147 153 10.1590/0037-8682-0039-2013 2-s2.0-84877975372
39. Fernandez-Soto L., Gonzalez A., Escobar-Jimenez F., Vazquez R., Ocete E., Olea N., Salmeron J., Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Archives of Internal Medicine 1998 158 13 1445 1448 10.1001/archinte.158.13.1445 2-s2.0-0032527967
40. Danilovic D. L. S., Mendes-Correa M. C., Chammas M. C., Zambrini H., Barros R. K., Marui S., Thyroid disturbance related to chronic hepatitis C infection: role of CXCL10. Endocrine Journal 2013 60 5 583 590 10.1507/endocrj.EJ12-0321 2-s2.0-84878480123
41. Antonelli A., Ferri C., Pampana A., Fallahi P., Nesti C., Pasquini M., Marchi S., Ferrannini E., Thyroid disorders in chronic hepatitis C. The American Journal of Medicine 2004 117 1 10 13 10.1016/j.amjmed.2004.01.023 2-s2.0-2942741109
42. Rodríguez-Torres M., Ríos-Bedoya C. F., Ortiz-Lasanta G., Marxuach-Cuétara A. M., Jiménez-Rivera J., Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Annals of Hepatology 2008 7 1 72 77 2-s2.0-41549098253
43. Ferri S., Muratori L., Lenzi M., Granito A., Bianchi F. B., Vergani D., HCV and autoimmunity. Current Pharmaceutical Design 2008 14 17 1678 1685 10.2174/138161208784746824 2-s2.0-47349098609
44. Menconi F., Hasham A., Tomer Y., Environmental triggers of thyroiditis: hepatitis C and interferon- α Journal of Endocrinological Investigation 2011 34 1 78 84 10.3275/7499 2-s2.0-79955459180
45. Testa A., Castaldi P., Fant V., Fiore G. F., Grieco V., De Rosa A., Pazardjiklian M. G., De Rosa G., Prevalence of HCV antibodies in autoimmune thyroid disease. European Review for Medical and Pharmacological Sciences 2006 10 4 183 186 2-s2.0-33748530661
46. Antonelli A., Ferri C., Ferrari S. M., Colaci M., Sansonno D., Fallahi P., Endocrine manifestations of hepatitis C virus infection. Nature Clinical Practice Endocrinology and Metabolism 2009 5 1 26 34 10.1038/ncpendmet1027 2-s2.0-57649165863
47. Metcalfe R. A., Ball G., Kudesia G., Weetman A. P., Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid 1997 7 3 421 424 10.1089/thy.1997.7.421 2-s2.0-0030750655
48. Boadas J., Rodriguez-Espinosa J., Enriquez J., Miralles F., Martinez-Cerezo F. J., Gonzalez P., Madoz P., Vilardell F., Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. Journal of Hepatology 1995 22 6 611 615 10.1016/0168-8278(95)80216-9 2-s2.0-0029070077
49. Ganne-Carrie N., Medini A., Coderc E., Seror O., Christidis C., Grimbert S., Trinchet J.-C., Beaugrand M., Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. Journal of Autoimmunity 2000 14 2 189 193 10.1006/jaut.1999.0360 2-s2.0-0033839428
50. Donati L., Antonelli A., Bertoni F., Moscogiuri D., Andreani M., Venturi S., Filippi T., Gasperini L., Neri S., Baschieri L., Clinical picture of endemic cretinism in central Apennines (Montefeltro). Thyroid 1992 2 4 283 290 10.1089/thy.1992.2.283 2-s2.0-0027064468
51. Indolfi G., Stagi S., Bartolini E., Salti R., De Martino M., Azzari C., Resti M., Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clinical Endocrinology 2008 68 1 117 121 10.1111/j.1365-2265.2007.03009.x 2-s2.0-36949030813
52. Pateron D., Hartmann D. J., Duclas-Vallee J. C., Jouanolle H., Beaugrand M., Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. Journal of Hepatology 1992 16 1-2 244 245 10.1016/S0168-8278(05)80124-2 2-s2.0-0026677613
53. Watanabe U., Hashimoto E., Hisamitsu T., Obata H., Hayashi N., The risk factor for development of thyroid disease during interferon- α therapy for chronic hepatitis C. The American Journal of Gastroenterology 1994 89 3 399 403 2-s2.0-0028266831
54. Carella C., Amato G., Biondi B., Rotondi M., Morisco F., Tucillo C., Chiuchiolo N., Signoriello G., Caporaso N., Lombardi G., Longitudinal study of antibodies against thyroid in patients undergoing interferon- α therapy for HCV chronic hepatitis. Hormone Research 1995 44 3 110 114 10.1159/000184606 2-s2.0-0029080477
55. Roti E., Minelli R., Giuberti T., Marchelli S., Schianchi C., Gardini E., Salvi M., Fiaccadori F., Ugolotti G., Neri T. M., Braverman L. E., Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. The American Journal of Medicine 1996 101 5 482 487 10.1016/S0002-9343(96)00259-8 2-s2.0-0030279780
56. Marazuela M., García-Buey L., González-Fernández B., García-Monzón C., Arranz A., Borque M. J., Moreno-Otero R., Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon- α therapy. Clinical Endocrinology 1996 44 6 635 642 10.1046/j.1365-2265.1996.751768.x 2-s2.0-0029955576
57. Carella C., Mazziotti G., Morisco F., Rotondi M., Cioffi M., Tuccillo C., Sorvillo F., Caporaso N., Amato G., The addition of ribavirin to interferon- α therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. European Journal of Endocrinology 2002 146 6 743 749 10.1530/eje.0.1460743 2-s2.0-0036299570
58. Teng Z. L., Gong W. J., Zhang S. Q., Sun Y. X., Ma X. H., Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy. Zhonghua Ganzangbing Zazhi 2013 21 2 101 104 2-s2.0-84896472733
59. Antonelli A., Ferri C., Fallahi P., Ferrari S. M., Ghinoi A., Rotondi M., Ferrannini E., Thyroid disorders in chronic hepatitis C virus infection. Thyroid 2006 16 6 563 572 10.1089/thy.2006.16.563 2-s2.0-33745993605
60. Giordano T. P., Henderson L., Landgren O., Chiao E. Y., Kramer J. R., El-Serag H., Engels E. A., Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. The Journal of the American Medical Association 2007 297 18 2010 2017 10.1001/jama.297.18.2010 2-s2.0-34248399089
61. Antonelli A., Ferri C., Galeazzi M., Giannitti C., Manno D., Mieli-Vergani G., Menegatti E., Olivieri I., Puoti M., Palazzi C., Roccatello D., Vergani D., Sarzi-Puttini P., Atzeni F., HCV infection: pathogenesis, clinical manifestations and therapy. Clinical and Experimental Rheumatology 2008 26 1, supplement 48 S39 S47 2-s2.0-42549131446
62. Mohran Z. Y., Abdel Kader N. A., Abdel Moez A. T., Abbas A. A., supclinical autoimmune thyroid disorders in Egyptian patients with untreated chronic hepatitis C virus infection. Journal of the Egyptian Society of Parasitology 2010 40 1 45 56 2-s2.0-77954077350
63. Russo M. W., Fried M. W., Side effects of therapy for chronic hepatitis C. Gastroenterology 2003 124 6 1711 1719 10.1016/S0016-5085(03)00394-9 2-s2.0-0037517079
64. Dalgard O., Bjøro K., Hellum K., Myrvang B., Bjøro T., Haug E., Bell H., Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: No association with either interferon dosage or efficacy of therapy. Journal of Internal Medicine 2002 251 5 400 406 10.1046/j.1365-2796.2002.00974.x 2-s2.0-0036091858
65. Friedrich-Rust M., Theobald J., Zeuzem S., Bojunga J., Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. Journal of Viral Hepatitis 2009 16 3 168 177 10.1111/j.1365-2893.2008.01059.x 2-s2.0-60349119647
66. Fentiman I. S., Thomas B. S., Balkwill F. R., Rubens R. D., Hayward J. L., Primary hypothyroidism associated with interferon therapy of breast cancer. The Lancet 1985 1 8438 1166 10.1016/S0140-6736(85)92475-4 2-s2.0-0021857987
67. de Oliveira Andrade L. J., Junior A. D., Costa Silva C. A., Nunes P., França L. S., Malta A. M. A., Paraná R., A meta-analysis of patients with chronic hepatitis C treated with interferon-alpha to determine the risk of autoimmune thyroiditis. Acta Gastroenterologica Latinoamericana 2011 41 2 104 110 2-s2.0-79960174155
68. Tran H. A., Reeves G. E. M., The spectrum of autoimmune thyroid disease in the short to medium term following interferon-therapy for chronic hepatitis C. International Journal of Endocrinology 2009 2009 5 241786 10.1155/2009/241786 2-s2.0-78751652478
69. Koh L. K. H., Greenspan F. S., Yeo P. P. B., Interferon- α induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997 7 6 891 896 10.1089/thy.1997.7.891 2-s2.0-0031465313
70. Wong V., Fu A. X.-L., George J., Cheung N. W., Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clinical Endocrinology 2002 56 6 793 798 10.1046/j.1365-2265.2002.01553.x 2-s2.0-0036067539
71. Mandac J. C., Chaudhry S., Sherman K. E., Tomer Y., The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. Hepatology 2006 43 4 661 672 10.1002/hep.21146 2-s2.0-33645986654
72. Czarnywojtek A., Zgorzalewicz-Stachowiak M., Waško R., Czepczynski R., Szczepanek-Parulska E., Waligorska-Stachura J., Kurdybacha P., Bereszyńska I., Florek E., Stangierski A., Zdanowska J., Nikisch E., Sowiński J., Ruchała M., Patients with chronic hepatitis type C and interferon-alpha-induced hyperthyroidism in two-years clinical follow-up. Neuroendocrinology Letters 2013 34 2 154 161 2-s2.0-84878240171
73. Andrade L. J. D. O., Atta A. M., D'Almeida A. Jr., Paranà R., Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin-a review. Brazilian Journal of Infectious Diseases 2008 12 2 144 148 2-s2.0-50949105109
74. Prummel M. F., Laurberg P., Interferon- α and autoimmune thyroid disease. Thyroid 2003 13 6 547 551 10.1089/105072503322238809 2-s2.0-0038168312
75. Savvas S. P., Papakostas N., Giannaris M., Malaktari S., Koskinas J., Archimandritis A. J., Interferon alpha-Induced hashimoto thyroiditis followed by transient graves disease in a patient with chronic HCV infection. Southern Medical Journal 2010 103 6 585 588 10.1097/SMJ.0b013e3181ddd952 2-s2.0-77953284943
76. Mammen J. S., Ghazarian S. R., Rosen A., Ladenson P. W., Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C. Thyroid 2013 23 9 1151 1158 10.1089/thy.2012.0565 2-s2.0-84884131164
77. Goldman M., Lambert P., Tasiaux N., Vereerstraeten P., Sabot J. P., Thoua Y., Toussaint C., Bidey S., Thyroid-stimulating immunoglobulins in mixed (type II) cryoglobulinemia associated with thyrotoxicosis. Arthritis and Rheumatism 1987 30 11 1318 1319 10.1002/art.1780301121 2-s2.0-0023444566
78. Castellano Higuera A., González Reimers E., Alarcó Hernández B., Santolaria Fernández F., Rodríguez Gaspar M., Hypotiroidism, hemolytic anemia and cryoglobulinemia in a patient with hepatitis C virus infection: efficacy of treatment with alpha-interferon. Anales de Medicina Interna 2003 20 7 391 392 2-s2.0-0042155841
79. Antonelli A., Ferri C., Fallahi P., Ferrari S. M., Sebastiani M., Ferrari D., Giunti M., Frascerra S., Tolari S., Franzoni F., Galetta F., Marchi S., Ferrannini E., High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. The American Journal of Gastroenterology 2008 103 10 2488 2494 10.1111/j.1572-0241.2008.02040.x 2-s2.0-53149107470
80. Antonelli A., Ferri C., Fallahi P., Giuggioli D., Nesti C., Longombardo G., Fadda P., Pampana A., Maccheroni M., Ferrannini E., Thyroid involvement in patients with HCV-related mixed cryoglobulinaemia. QJM 2004 97 8 499 506 10.1093/qjmed/hch088 2-s2.0-4344600903
81. Antonelli A., Ferri C., Fallahi P., Thyroid cancer in patients with hepatitis C infection. Journal of the American Medical Association 1999 281 17 1588 10.1001/jama.281.17.1588 2-s2.0-0033526338
82. Montella M., Crispo A., Pezzullo L., Is hepatitis C virus infection associated with thyroid cancer? A case-control study. International Journal of Cancer 2000 87 4 611 612
83. Montella M., Crispo A., de Bellis G., Izzo F., Frigeri F., Ronga D., Spada O., Mettivier V., Tamburini M., Cuomo O., HCV and cancer: a case-control study in a high-endemic area. Liver 2001 21 5 335 341 10.1034/j.1600-0676.2001.210506.x 2-s2.0-0034812142
84. Antonelli A., Ferri C., Fallahi P., Nesti C., Zignego A. L., Maccheroni M., Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clinical and Experimental Rheumatology 2002 20 5 693 696 2-s2.0-0036709483
85. Fiore E., Rago T., Latrofa F., Provenzale M. A., Piaggi P., Delitala A., Scutari M., Basolo F., Di Coscio G., Grasso L., Pinchera A., Vitti P., Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocrine-Related Cancer 2011 18 4 429 437 10.1530/ERC-11-0028 2-s2.0-79960839823
86. Lee M.-H., Yang H.-I., Lu S.-N., Jen C.-L., You S.-L., Wang L.-Y., Wang C.-H., Chen W. J., Chen C.-J., Hsieh C. Y., Lee H. S., Yang P. M., Chen C. H., Chen J. D., Huang S. P., Jan C. F., Chen T. H. H., Sun C. A., Wu M. H., Chen S. Y., Chu K. E., Ho S. C., Lu T. G., Wu W. P., Ou T. Y., Lin C. G., Shih K. C., Chung W. S., Li C., Chen C. C., How W. C., Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. The Journal of Infectious Diseases 2012 206 4 469 477 10.1093/infdis/jis385 2-s2.0-84866898184
87. Antonelli A., Ferri C., Fallahi P., Pampana A., Ferrari S. M., Barani L., Marchi S., Ferrannini E., Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007 17 5 447 451 10.1089/thy.2006.0194 2-s2.0-34249947560
88. Neri S., Boraschi P., Antonelli A., Falaschi F., Baschieri L., Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. The American Journal of Industrial Medicine 1996 30 5 588 595
89. Antonelli A., Fallahi P., Ferrari S. M., Carpi A., Berti P., Materazzi G., Minuto M., Guastalli M., Miccoli P., Dedifferentiated thyroid cancer: a therapeutic challenge. Biomedicine and Pharmacotherapy 2008 62 8 559 563 10.1016/j.biopha.2008.07.056 2-s2.0-55149090490
90. Antonelli A., Bocci G., La Motta C., Ferrari S. M., Fallahi P., Fioravanti A., Sartini S., Minuto M., Piaggi S., Corti A., Alì G., Berti P., Fontanini G., Danesi R., Da Settimo F., Miccoli P., Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism 2011 96 2 E288 E296 10.1210/jc.2010-1905 2-s2.0-79951709994
91. Martocchia A., Falaschi P., Amino acid sequence homologies between HCV polyprotein and thyroid antigens. Internal and Emergency Medicine 2007 2 1 65 67 10.1007/s11739-007-0018-x 2-s2.0-34249874890
92. Tomer Y., Villanueva R., Hepatitis C and thyroid autoimmunity: is there a link? The American Journal of Medicine 2004 117 1 60 61 10.1016/j.amjmed.2004.04.004 2-s2.0-2942752175
93. Tomer Y., Blackard J. T., Akeno N., Interferon alpha treatment and thyroid dysfunction. Endocrinology and Metabolism Clinics of North America 2007 36 4 1051 1066 10.1016/j.ecl.2007.07.001 2-s2.0-35648940270
94. Patzwahl R., Meire V., Ramadori G., Mihm S., Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-suptractive hybridization. Journal of Virology 2001 75 3 1332 1338 10.1128/JVI.75.3.1332-1338.2001 2-s2.0-0035138173
95. Mihm S., Schweyer S., Ramadori G., Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN- γ and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. Journal of Medical Virology 2003 70 4 562 570 10.1002/jmv.10431 2-s2.0-0037708311
96. Antonelli A., Ferrari S. M., Giuggioli D., Ferrannini E., Ferri C., Fallahi P., Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmunity Reviews 2014 13 3 272 280 10.1016/j.autrev.2013.10.010 2-s2.0-84891738394
97. Antonelli A., Ferrari S. M., Corrado A., Ferrannini E., Fallahi P., CXCR3, CXCL10 and type 1 diabetes. Cytokine & Growth Factor Reviews 2014 25 1 57 65 10.1016/j.cytogfr.2014.01.006
98. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S. M., Barani L., Ferrannini E., Serio M., Increase of interferon- γ -inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clinical Endocrinology 2006 64 2 189 195 10.1111/j.1365-2265.2006.02447.x 2-s2.0-33645037851
99. Antonelli A., Rotondi M., Fallahi P., Grosso M., Boni G., Ferrari S. M., Romagnani P., Serio M., Mariani G., Ferrannini E., Iodine-131 given for therapeutic purposes modulates differently interferon- γ -inducible α -chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. The Journal of Clinical Endocrinology and Metabolism 2007 92 4 1485 1490 10.1210/jc.2006-1571 2-s2.0-34147096595
100. Antonelli A., Fallahi P., Rotondi M., Ferrari S. M., Serio M., Miccoli P., Serum levels of the interferon- γ -inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. British Journal of Surgery 2006 93 10 1226 1231 10.1002/bjs.5401 2-s2.0-33749589416
101. Antonelli A., Rotondi M., Fallahi P., Ferrari S. M., Paolicchi A., Romagnani P., Serio M., Ferrannini E., Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006 34 1-2 32 38 10.1016/j.cyto.2006.03.012 2-s2.0-33744513348
102. Matskevich A. A., Strayer D. S., Exploiting hepatitis C virus activation of NF B to deliver HCV-responsive expression of interferons α and γ Gene Therapy 2003 10 22 1861 1873 10.1038/sj.gt.3302091 2-s2.0-0141663663
103. + T cells with memory-phenotype in patients with chronic hepatitis C. Journal of Medical Virology 2002 67 2 162 170 10.1002/jmv.2205 2-s2.0-0036252191
104. Loetscher M., Loetscher P., Brass N., Meese E., Moser B., Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. European Journal of Immunology 1998 28 11 3696 3705
105. Qin S., Rottman J. B., Myers P., Kassam N., Weinblatt M., Loetscher M., Koch A. E., Moser B., Mackay C. R., The chemokine receptors CXCR3 and CCR5 mark supsets of T cells associated with certain inflammatory reactions. The Journal of Clinical Investigation 1998 101 4 746 754 10.1172/JCI1422 2-s2.0-0032519405
106. Rotondi M., Rosati A., Buonamano A., Lasagni L., Lazzeri E., Pradella F., Fossombroni V., Cirami C., Liotta F., La Villa G., Serio M., Bertoni E., Salvadori M., Romagnani P., High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. The American Journal of Transplantation 2004 4 9 1466 1474 10.1111/j.1600-6143.2004.00525.x 2-s2.0-4344648638
107. Pupilli C., Giannini S., Marchetti P., Lupi R., Antonelli A., Malavasi F., Takasawa S., Okamoto H., Ferrannini E., Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. Diabetes 1999 48 12 2309 2315 10.2337/diabetes.48.12.2309 2-s2.0-0033512420
108. Antonelli A., Tuomi T., Nannipieri M., Fallahi P., Nesti C., Okamoto H., Groop L., Ferrannini E., Autoimmunity to CD38 and GAD in type I and type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002 45 9 1298 1306 10.1007/s00125-002-0886-6 2-s2.0-0036383410
109. Antonelli A., Baj G., Marchetti P., Fallahi P., Surico N., Pupilli C., Malavasi F., Ferrannini E., Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001 50 5 985 991 10.2337/diabetes.50.5.985 2-s2.0-0035038546
110. Antonelli A., Ferri C., Fallahi P., Ferrari S. M., Giuggioli D., Colaci M., Manfredi A., Frascerra S., Franzoni F., Galetta F., Ferrannini E., CXCL10 (α) and CCL2 (β) chemokines in systemic sclerosis-a longitudinal study. Rheumatology 2008 47 1 45 49 10.1093/rheumatology/kem313 2-s2.0-37349045796
111. Antonelli A., Fazzi P., Fallahi P., Ferrari S. M., Ferrannini E., Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest 2006 130 2 526 532 10.1378/chest.130.2.526 2-s2.0-33747595238
112. Takeuchi M., Oh-I K., Suzuki J., Hattori T., Takeuchi A., Okunuki Y., Usui Y., Usui M., Elevated serum levels of CXCL9/monokine induced by interferon- γ and CXCL10/interferon- γ -inducible protein-10 in ocular sarcoidosis. Investigative Ophthalmology and Visual Science 2006 47 3 1063 1068 10.1167/iovs.05-0966 2-s2.0-33645410753
113. Antonelli A., Delle Sedie A., Fallahi P., Ferrari S. M., Maccheroni M., Ferrannini E., Bombardieri S., Riente L., High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. Journal of Rheumatology 2006 33 10 2026 2028 2-s2.0-33750017049
114. Antonelli A., Fallahi P., Sedie A. D., Ferrari S. M., Maccheroni M., Bombardieri S., Riente L., Ferrannini E., High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 2008 41 7 537 542 10.1080/08916930802170401 2-s2.0-54549124854
115. Antonelli A., Ferrari S. M., Fallahi P., Frascerra S., Santini E., Franceschini S. S., Ferrannini E., Monokine induced by interferon γ (IFN γ) (CXCL9) and IFN γ inducible T-cell α -chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor- γ agonists. The Journal of Clinical Endocrinology and Metabolism 2009 94 5 1803 1809 10.1210/jc.2008-2450 2-s2.0-66149120609
116. Antonelli A., Fallahi P., Nesti C., Pupilli C., Marchetti P., Takasawa S., Okamoto H., Ferrannini E., Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clinical and Experimental Immunology 2001 126 3 426 431 10.1046/j.1365-2249.2001.01683.x 2-s2.0-0035655620
117. Antonelli A., Fallahi P., Rotondi M., Ferrari S. M., Romagnani P., Grosso M., Ferrannini E., Serio M., Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. European Journal of Endocrinology 2006 154 5 651 658 10.1530/eje.1.02137 2-s2.0-33744518678
118. Hiromatsu Y., Yang D., Bednarczuk T., Miyake I., Nonaka K., Inoue Y., Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. Journal of Clinical Endocrinology and Metabolism 2000 85 3 1194 1199 10.1210/jc.85.3.1194 2-s2.0-0034453080
119. Romagnani P., Rotondi M., Lazzeri E., Lasagni L., Francalanci M., Buonamano A., Milani S., Vitti P., Chiovato L., Tonacchera M., Bellastella A., Serio M., Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' Disease. The American Journal of Pathology 2002 161 1 195 206 10.1016/S0002-9440(10)64171-5 2-s2.0-0036317941
120. Antonelli A., Rotondi M., Ferrari S. M., Fallahi P., Romagnani P., Franceschini S. S., Serio M., Ferrannini E., Interferon- γ -inducible α -chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor- γ agonists. The Journal of Clinical Endocrinology and Metabolism 2006 91 2 614 620 10.1210/jc.2005-1689 2-s2.0-32544456285
121. Gowans E. J., Distribution of markers of hepatitis C virus infection throughout the body. Seminars in Liver Disease 2000 20 1 85 102 10.1055/s-2000-9503 2-s2.0-0033934875
122. Antonelli A., Ferri C., Fallahi P., Ferrari S. M., Frascerra S., Carpi A., Nicolini A., Ferrannini E., α -Chemokine CXCL10 and β -chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism: Clinical and Experimental 2008 57 9 1270 1277 10.1016/j.metabol.2008.04.023 2-s2.0-48849102177
123. Antonelli A., Ferri C., Ferrari S. M., De Marco S., Di Domenicantonio A., Centanni M., Pupilli C., Villa E., Menichetti F., Fallahi P., Interleukin-1 β C-X-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. Journal of Interferon and Cytokine Research 2010 30 11 835 842 10.1089/jir.2010.0024 2-s2.0-78149332071
124. Antonelli A., Ferri C., Ferrari S. M., Di Domenicantonio A., Ferrari P., Pupilli C., Nicolini A., Zignego A. L., Marchi S., Fallahi P., The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating interleukin-6, but not of tumour necrosis factor-alpha. Clinical and Experimental Rheumatology 2011 29 1, supplement 64 S17 S22 2-s2.0-79960426065
125. Villa E., Karampatou A., Camm C., Di Leo A., Luongo M., Ferrari A., Petta S., Losi L., Taliani G., Trande P., Lei B., Graziosi A., Bernabucci V., Critelli R., Pazienza P., Rendina M., Antonelli A., Francavilla A., Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011 140 3 818 829 10.1053/j.gastro.2010.12.027 2-s2.0-79952308232
126. Müller M., Carter S. L., Hofer M. J., Manders P., Getts D. R., Getts M. T., Dreykluft A., Lu B., Gerard C., King N. J. C., Campbell I. L., CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. Journal of Immunology 2007 179 5 2774 2786 10.4049/jimmunol.179.5.2774 2-s2.0-35349024802
127. Putheti P., Morris M., Stawiarz L., Teleshova N., Kivisäkk P., Pashenkov M., Kouwenhoven M., Wiberg M. K., Bronge L., Huang Y.-M., Söderström M., Hillert J., Link H., Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables. European Journal of Neurology 2003 10 5 529 535 10.1046/j.1468-1331.2003.00638.x 2-s2.0-0142119367
128. Stiles L. N., Liu M. T., Kane J. C., Lane T. E., CXCL10 and trafficking of virus-specific T cells during coronavirus-induced demyelination. Autoimmunity 2009 42 6 484 491 10.1080/08916930902810708 2-s2.0-70249092892
129. Wildner G., Kaufmann U., What causes relapses of autoimmune diseases? The etiological role of autoreactive T cells. Autoimmunity Reviews 2013 12 11 1070 1075 10.1016/j.autrev.2013.04.001 2-s2.0-84881548127